An HIVgp41 vaccine protects CD4 central memory T cells in SHIV-infected macaques

Vaccine

Volumn 30, Issue 48, 2012, Pages 6883-6891

  Vieillard, Vincent ^a,b   Dereuddre Bosquet, Nathalie ^c,d   Mangeot Méderlé, Isabelle ^c,d   Le Grand, Roger ^c,d   Debré, Patrice ^a,b  

^a Inst Natl de la Sante Recherche   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

CD4+ T cell depletion; HIV 1; NKp44L; Therapeutic vaccination

Indexed keywords

3S PEPTIDE; CD4 ANTIGEN; GLYCOPROTEIN GP 41; KEYHOLE LIMPET HEMOCYANIN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; PEPTIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MACACA; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM; SIMIAN IMMUNODEFICIENCY VIRUS; SPLEEN; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VACCINATION; VIRUS LOAD; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; APOPTOSIS; BLOOD; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FLOW CYTOMETRY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; IMMUNOLOGIC MEMORY; LYMPH NODES; MACACA; RECTUM; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SPLEEN;

EID: 84868203489     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.004     Document Type: Article

References (46)

1. Stevenson M. HIV-1 pathogenesis. Nat Med 2003, 9(November (11)):853-860.
2. Finkel T.H., Tudor-Williams G., Banda N.K., Cotton M.F., Curiel T., Monks C., et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995, 191(Febrary (2)):129-134.
3. Varbanov M., Espert L., Biard-Piechaczyk M. Mechanisms of CD4 T-cell depletion triggered by HIV-1 viral proteins. AIDS Rev 2006, 8(October-December (4)):221-236.
4. Douek D.C., Roederer M., Koup R.A. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009, 60:471-484.
5. Sodora D.L., Allan J.S., Apetrei C., Brenchley J.M., Douek D.C., Else J.G., et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med 2009, 15(August (8)):861-865.
6. Ward J., Bonapart M., Sacks J., Guterman J., Fogli M., Mavilio D., et al. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood 2007, 110(August (4)):1207-1214.
7. Fausther-Bovendo H., Sol-Foulon N., Candotti D., Agut H., Schwartz O., Debré P., et al. HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on CD4+ T cells. AIDS 2009, 23(June (9)):1077-1087.
8. Vieillard V., Strominger J.L., Debré P. NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci USA 2005, 102(August (31)):10981-10986.
9. Fausther-Bovendo H., Vieillard V., Sagan S., Bismuth G., Debré P. HIV gp41 Engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway. PLoS Pathog 2010, (July (6)):e1000975.
10. Vieillard V., Costagliola D., Simon A., Debré P. Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection. AIDS 2006, 20(September (14)):1795-1804. French Asymptomatiques à Long Terme (ALT) Study Group.
11. Mannioui A., Bourry O., Sellier P., Delache B., Brochard P., Andrieu T., et al. Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques. Retrovirology 2009, 6(November (23)):106.
12. Vieillard V., Le Grand R., Dausset J., Debré P. A vaccine strategy against AIDS: an HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques. Proc Natl Acad Sci USA 2008, 105(Febrary (6)):2100-2104.
13. Arnoult D., Karbowski M., Youle R.J. Caspase-dependent and -independent T-cell death pathways in pathogenic simian immunodeficiency virus infection: relationship to disease progression. Cell Death Differ 2003, 10(November (11)):1240-1252.
14. Mee E.T., Berry N., Ham C., Sauermann U., Maggiorella M.T., Martinon F., et al. Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques. Immunogenetics 2009, 61(May (5)):327-339.
15. Aarnink A., Dereuddre-Bosquet N., Vaslin B., Le Grand R., Winterton P., Apoil P.A., et al. Influence of the MHC genotype on the progression of experimental SIV infection in the Mauritanian cynomolgus macaque. Immunogenetics 2011, 63(May (5)):267-274.
16. Gougeon M.L. Apoptosis as an HIV strategy to escape immune attack. Nat Rev Immunol 2003, 3(May (5)):392-404.
17. Vieillard V., Habib R.E., Brochard P., Delache B., Bovendo H.F., Calvo J., et al. CCR5 or CXCR4 use influences the relationship between CD4 cell depletion, NKp44L expression and NK cytotoxicity in SHIV-infected macaques. AIDS 2008, 22(January (2)):185-192.
18. Sousa A.E., Carneiro J., Meier-Schellersheim M., Grossman Z., Victorino R.M. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002, 169(September (6)):3400-3406.
19. Simon V., Ho D.D., Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006, 368(August (9534)):489-504.
20. Hazenberg M.D., Hamann D., Schuitemaker H., Miedema F. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol 2000, 1(October (4)):285-289.
21. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417(May (6684)):95-98.
22. Haase A.T. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Ann Rev Immunol 1999, 17:625-656.
23. McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33(October 29 (4)):542-554.
24. Meyaard L., Otto S.A., Jonker R.R., Mijnster M.J., Keet R.P., Miedema F. Programmed death of T cells in HIV-1 infection. Science 1992, 257(July (5067)):217-219.
25. Gougeon M.L., Montagnier L. Apoptosis in AIDS. Science 1993, 260(November (5138)):1269-1270.
26. Appay V., Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008, 214(January (2)):231-241.
27. Hazenberg M.D., Otto S.A., van Benthem B.H., Roos M.T., Coutinho R.A., Lange J.M., et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003, 17(September (13)):1881-1888.
28. Cicala C., Arthos J., Rubbert A., Selig S., Wildt K., Cohen O.J., et al. HIV-1 envelope induces activation of caspase-3 and cleavage of focal adhesion kinase in primary human CD4(+) T cells. Proc Natl Acad Sci USA 2000, 97(February (3)):1178-1183.
29. Garg H., Blumenthal R. HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J Leukoc Biol 2006, 79(February (2)):351-362.
30. Buzon M.J., Massanella M., Libre J.M., Esteve A., Dahl V., Puertas M.C., et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010, 16(April (4)):460-465.
31. El-Sadr W.M., Lundgren J.D., Neaton J.D., Gordin F., Abrams D., Arduino R.C., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355(November (22)):2283-2296.
32. Guiguet M., Boué F., Cadranel J., Lang J.M., Rosenthal E., Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009, 10(December (12)):1152-1159.
33. Abrams D., Lévy Y., Losso M.H., Babiker A., Collins G., Cooper D.A., et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009, 361(October (16)):1548-1559.
34. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelièvre J.D., et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009, 119(April (4)):997-1007.
35. Diop O.M., Gueye A., Dias-Tavares M., Kornfeld C., Faye A., Ave P., et al. High levels of viral replication during primary simian immunodeficiency virus SIVagm infection are rapidly and strongly controlled in African green monkeys. J Virol 2000, 74(August (16)):7538-7547.
36. Hirsch V.M. What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS?. AIDS Rev 2004, 6(January-March (1)):40-53.
37. Beaumier C.M., Harris L.D., Goldstein S., Klatt N.R., Whitted S., McGinty J., et al. CD4 downregulation by memory CD4+ T cells in vivo renders African green monkeys resistant to progressive SIVagm infection. Nat Med 2009, 15(August (8)):879-885.
38. Okoye A., Meir-Schellersheim M., Brenchley J.M., Hagen S.I., Walker J.M., Rohankhedkar M., et al. Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med 2007, 204(September (9)):2171-2185.
39. Lanzavecchia A., Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005, 17(June (3)):326-332.
40. Mattapallil J.J., Douek D.C., Hill B., Nishimura Y., Martin M., Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434(April (7037)):1093-1097.
41. Shedlock D.J., Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300(April (5617)):337-339.
42. Brenchley J.M., Silvestri G., Douek D.C. Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity 2010, 32(June (6)):737-742.
43. Potter S.J., Lacabaratz C., Lambotte O., Perez-Patrigeon S., Vingert B., Sinet M., et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 2007, 81(December (24)):13904-13915.
44. Poonia B., Salvato M.S., Yagita H., Maeda T., Okumura K., Pauza C.D. Treatment with anti-FASL antibodies preserves memory lymphocytes and virus-specific cellular immunity in macaques challanged with simian immunodeficiency. Blood 2009, 114(August (6)):1196-1204.
45. Letvin N.L. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006, 312(June (5779)):1530-1533.
46. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15(March (3)):293-299.